Alzheimer's disease risk 'halved' by eating one food every week
A popular food found in most kitchens could help lower the risk of dementia by almost half. A new study has found that eating one egg per week was linked to a 47 per cent reduction in the chance of developing Alzheimer's disease.
This was the case compared to people who consumed eggs less than once each month. It was also found that people who ate eggs had a reduced build up of the toxic proteins associated with Alzheimer's.
However, it is important to note that some authors of the study, which was published in The Journal of Nutrition, received funding from the Egg Nutrition Centre in the US. Alzheimer's disease is the most common form of dementia in the world.
As reported by Medical News Today, the study included data from 1,024 older adults with an average age of 81.4. Participants attended annual check-ups and completed food frequency questionnaires, and the researchers followed them for an average of 6.7 years.
Over this period of time, just over a quarter of them developed Alzheimer's disease. Analysis of this information showed that people who consumed at least one egg per week had a 47 per cent reduced risk of developing Alzheimer's during follow-up compared with those eating one egg per month or fewer.
In the same study, a post-mortem on the brains of 578 participants revealed that those who ate one or more eggs each week were more likely to have less Alzheimer's-associated protein build up.
Choline and omega-3
It is thought the brain-boosting benefits of eggs come from two nutrients, choline and omega-3. Previous studies have shown that choline is vital for cognitive function.
Study authors said explained that 'choline modulates the expression of key genes related to memory, learning, and cognitive functions via epigenetic mechanisms.' They also described eggs as a 'top food source' of choline.
Eggs are also rich in omega-3 fatty acids, which support brain health as we age. Study authors suggested that the choline and omega-3s in eggs might have a 'synergistic' effect, whereby they join forces to protect brain health during ageing.
Previous research has also shown that people with Alzheimer's are more likely to be deficient in omega-3s and choline.
However, the researchers concluded that further investigation was needed. They said: 'Once replicated in other prospective cohorts and confirmed by clinical trials, these findings may have important public health implications for reducing the population's risk of [Alzheimer's].'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mirror
4 hours ago
- Daily Mirror
'Breakthrough' new drug could stop ageing and halt cell self-destruction
An 'extraordinary' new class of drugs are set to undergo human trials after researchers believe they could become the first medication to reverse the effects of ageing Scientists believe they've developed a drug that could halt human ageing and reverse the impacts of 'cell death', with trials due to kick off later this year. Cell death is a natural, and essential, process that takes various forms. One such form is necrosis, an unregulated type of cell death that can lead to premature cellular destruction. During necrosis, affected cells swell until they burst, spilling their contents into the surrounding area, potentially causing chronic inflammation, genetic instability, and in some instances, tumours. This process has been associated with numerous diseases, including Alzheimer's, Parkinson's, various cancers, and kidney disease. The world-renowned cancer journal, Oncogene, highlighted in May that a study into kidney disease could help researchers gain a better understanding of how necrosis operates and how to fight it, reports the Express. Dr Carina Kern, formerly a geneticist at University College London and now CEO of biotech firm LinkGevity, led the study. She believes a new category of drugs, dubbed 'anti-nectrotics', could be the first medication used to reverse the effects of ageing. Part of Dr Kern's motivation for her involvement in the project stems from her childhood experience of witnessing her grandmother's health rapidly decline due to an age-related illness. "At the time, I could not comprehend how I was so easily cured of nearly any injury, and I would be back to normal. But with her, the doctors just said 'you can't intervene-it's just ageing,'" she explained. Years later, after observing such deterioration, Dr Kern formulated the "Blueprint Theory" of ageing, which delves into the roots of ageing and identifies points for potential intervention to stave off illness. A key element identified in her research is necrosis, which Kern asserts is fundamentally a "loss of calcium-ion gradients." She elaborates: "Levels of calcium inside the cell are typically 10,000 to 100,000 times lower than outside. Calcium is a key signalling molecule, meaning it controls lots of different processes within your cell. "And so upon stress, you lose this regulation and then you're initiating multiple pathways in a heightened and really destructive manner within the cell." Although necrosis has been known for over a century and was further examined under microscopes in the 1970s, there hasn't been significant advancement in preventing its role in severe diseases. However, Dr Kern, alongside a team of renal experts, might be on the verge of a discovery targeting kidney disease that could also have implications for anti-ageing treatments. Dr Kern said: "It was thought it was just too complex a process to intervene in. What we've managed to identify for the first time is that you can block necrosis, but you have to block more than one molecular target... When we did that, we saw up to 90 per cent of suppression of necrosis." His colleague and co-author of the study, Dr Keith Siew, commented: "The by far the most in-demand organ, and the one you're most likely to die on a waiting list for. "Some people think dialysis just fixes the problem, but the mortality rate of dialysis is that every year you're on dialysis, you lose 10 per cent of survival." Having collaborated with NASA to explore how space travel impacts renal function, particularly when astronauts are exposed to cosmic radiation beyond Earth's magnetosphere, Dr Siew noted:. "Only 24 people have left the protection of Earth's magnetic field. You might feel fine on the way, but will you need dialysis on the way back?". He suggested that "Anti-necrotics could be a way to make those tissues and organs resilient enough to withstand that damage and pause cell death." Despite their groundbreaking work, both Kern and Siew maintain a cautious stance, describing themselves as "professional sceptics" regarding the potential success of the anti-necrotic drug, with clinical trials set to commence in 2025. Dr Siew emphasised the need for robust evidence: "Extraordinary claims require extraordinary evidence," he said. "Until that data is rock solid...a lot of people will view this skeptically and rightfully so."
Daily Mirror
14 hours ago
- Daily Mirror
Alzheimer's disease risk 'halved' by eating one food every week
This popular food is found in most kitchens and could have brain-boosting properties. A popular food found in most kitchens could help lower the risk of dementia by almost half. A new study has found that eating one egg per week was linked to a 47 per cent reduction in the chance of developing Alzheimer's disease. This was the case compared to people who consumed eggs less than once each month. It was also found that people who ate eggs had a reduced build up of the toxic proteins associated with Alzheimer's. However, it is important to note that some authors of the study, which was published in The Journal of Nutrition, received funding from the Egg Nutrition Centre in the US. Alzheimer's disease is the most common form of dementia in the world. As reported by Medical News Today, the study included data from 1,024 older adults with an average age of 81.4. Participants attended annual check-ups and completed food frequency questionnaires, and the researchers followed them for an average of 6.7 years. Over this period of time, just over a quarter of them developed Alzheimer's disease. Analysis of this information showed that people who consumed at least one egg per week had a 47 per cent reduced risk of developing Alzheimer's during follow-up compared with those eating one egg per month or fewer. In the same study, a post-mortem on the brains of 578 participants revealed that those who ate one or more eggs each week were more likely to have less Alzheimer's-associated protein build up. Choline and omega-3 It is thought the brain-boosting benefits of eggs come from two nutrients, choline and omega-3. Previous studies have shown that choline is vital for cognitive function. Study authors said explained that 'choline modulates the expression of key genes related to memory, learning, and cognitive functions via epigenetic mechanisms.' They also described eggs as a 'top food source' of choline. Eggs are also rich in omega-3 fatty acids, which support brain health as we age. Study authors suggested that the choline and omega-3s in eggs might have a 'synergistic' effect, whereby they join forces to protect brain health during ageing. Previous research has also shown that people with Alzheimer's are more likely to be deficient in omega-3s and choline. However, the researchers concluded that further investigation was needed. They said: 'Once replicated in other prospective cohorts and confirmed by clinical trials, these findings may have important public health implications for reducing the population's risk of [Alzheimer's].'
Scottish Sun
21 hours ago
- Scottish Sun
Ozempic-like fat jabs are BETTER than common drug at reducing dementia risk, study finds
Plus, all the ways you can lower your dementia risk if you have type 2 diabetes WIN WIN Ozempic-like fat jabs are BETTER than common drug at reducing dementia risk, study finds Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) FAT jabs are better than widely prescribed metformin when it comes to curbing dementia risk in people with type 2 diabetes, say scientists. While both medications demonstrate neuroprotective properties, no comparison has been made up until now. Sign up for Scottish Sun newsletter Sign up 1 GLP-1 receptor agonists have recently gained popularity as a weight loss medication Credit: Getty Metformin is generally the first-line medication for type 2 diabetes, while GLP-1 receptor agonists are often used as second-line or add-on therapy when metformin is not sufficient or tolerated. In recent times, GLP-1 receptor agonists have gained popularity as a weight loss medication due to their ability to suppress appetite and promote feelings of fullness. Previously published research indicated people with type 2 diabetes have a significantly increased risk of developing dementia, with some studies reporting a 70 per cent higher risk compared to those without diabetes. And both GLP-1 receptor agonists and metformin have been shown to protect the brains of people with type 2 diabetes. But in the largest study of its kind, published in BMJ Open Diabetes Research & Care, GLP-1 receptor agonists were found to trump metformin when it comes to dementia risk. Researchers analysed health records from the period 2004 to 2024 to track the development of dementia in patients with type 2 diabetes who were treated with either GLP-1 receptor agonists or metformin for at least six consecutive months. While there was no significant difference in vascular dementia risk between the two types of drug, GLP-1 receptor agonist use was associated with a significantly lower risk of developing dementia, overall. Specifically, taking GLP-1 receptor agonists was linked to a lower risk of developing Alzheimer's disease, and a 25 per cent lower risk of developing non-vascular dementias than metformin use. These positive effects were evident across all age groups, but with the strongest effect among the over 60s, women, and those of white ethnicity. Risk of death from any cause was also found to be lower - nearly 5 per cent of those treated with GLP-1 receptor agonists died compared with nearly 9 per cent of those treated with metformin. The 14 science-backed ways to prevent dementia 'Both medications demonstrate neuroprotective properties, such as reducing neuroinflammation and oxidative stress, improving insulin sensitivity, and enhancing cerebrovascular health, which likely contribute to their benefits in overall dementia,' explain the researchers. But unlike metformin, GLP-1 receptor agonists exert direct central nervous system effects by crossing the blood-brain barrier, they add. The researchers point out their tracking period, while sufficient for observing dementia outcomes, may not fully capture long-term cognitive effects, especially given the progressive nature of Alzheimer's disease. But they conclude: "Given the severe societal, familial , and economic burden of diabetes-related dementia, these findings raise important considerations about the tole of GLP-1 [receptor agonists] as first-line therapies in [type 2 diabetes] management. "While further long-term studies are warranted to validate these results, integrating GLP-1 [receptor agonists] as primary therapeutic agents may represent a paradigm shift in preventing the cognitive complications of diabetes.' All GLP-1 medicines are prescription only medicines, which means they can only be prescribed by a healthcare professional. GLP-1 medicines can also be purchased privately. If you want to get a GLP-1 medicine privately, a consultation with a healthcare professional must happen before the prescription can be issued, so the prescriber can carry out proper checks and make sure you are aware of the benefits and risks of taking the medicine. GLP-1 medicines should not be bought from unregulated sellers such as beauty salons or via social media, or from anywhere without a prior consultation with a healthcare professional. The Medicines & Healthcare products Regulatory Agency (MHRA) has had reports of people experiencing severe side effects from fake GLP-1 medicines.
